Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
How Long Can Lu-177 DOTATATE Keep My Carcinoid Tumor Stable? What Progression-Free Survival Data Says About Your Timeline
The landmark NETTER-1 trial found that more than half of midgut carcinoid tumor patients had not progressed at 20 months on Lu-177 DOTATATE. Here is what the progression-free survival data — from clinical trials and real-world studies — may mean for your personal timeline.
Will Lu-177 PSMA Cause Dry Mouth and Salivary Gland Damage — What Men with Bone Metastases Should Know
Dry mouth is one of the most commonly reported side effects of Lu-177 PSMA therapy. Here is what the research shows about why it happens, how often, whether it goes away, and what you and your care team can do about it.
Traveling Between Lu-177 DOTATATE Infusions: What Patients Need to Know About Radiation Safety and Logistics
After each Lu-177 DOTATATE infusion, your body carries low levels of radiation for several days. Here is what you need to know about protecting your family, navigating airport security, and planning travel during your PRRT course.
What Should My Spouse or Caregiver Know About Helping Me Through Lu-177 PSMA Treatment for Metastatic Prostate Cancer — A Practical Guide for Partners
If your partner is starting Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer, this plain-language guide covers radiation safety at home, practical day-to-day support, emotional caregiving, and how to look after yourself through every cycle.
My NETs Diagnosis Is New — Do I Have to Wait Until Other Treatments Fail Before I Can Get Lu-177 DOTATATE, or Can I Access It Earlier?
A new GEP-NETs diagnosis raises an urgent question: do you have to fail other treatments first before you can get Lu-177 DOTATATE? The answer depends on your tumor grade, receptor status, and the latest clinical evidence — and the landscape is shifting fast.
What Are My Real Chances of Qualifying for Lu-177 PSMA Therapy If My PSMA PET Scan Shows Mixed Results — Some Lesions Positive, Some Not?
A mixed PSMA PET scan — where some lesions light up and others don't — is one of the most confusing results a man with metastatic prostate cancer can receive. This plain-language guide explains exactly how doctors read those mixed results, what the VISION trial criteria actually say, and what your next steps should be.
Can I Combine Lu-177 DOTATATE with My Somatostatin Analog (Octreotide or Lanreotide) for Carcinoid Tumor? What Does the Evidence Say About Dual Therapy?
If you have a carcinoid tumor and are already taking octreotide or lanreotide, you may wonder whether Lu-177 DOTATATE can be added — and whether that combination is safe and supported by evidence. Here is what the research actually says.
What Can I Realistically Expect from Lu-177 DOTATATE for a Metastatic Neuroendocrine Tumor — How Do Doctors Measure Whether It Is Working?
If you have a metastatic neuroendocrine tumor, you may wonder what Lu-177 DOTATATE can realistically do for you — and how your care team will know if it is working. This guide walks you through the key outcomes from major clinical trials, the tools doctors use to track response, and the realistic range of results patients may experience.
What Are My Options If Lu-177 DOTATATE Stops Working for My Gastroenteropancreatic Neuroendocrine Tumor — and What Does the Evidence Say About Next Steps?
If your GEP-NET has progressed after Lu-177 DOTATATE (PRRT), you still have meaningful options. This evidence-based guide walks through re-treatment, targeted therapies, chemotherapy, emerging alpha-particle therapy, clinical trials, and how to decide what comes next.
How Does Lu-177 DOTATATE Compare to Other Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors — What Should Patients Know Before Choosing?
GEP-NET patients face several treatment paths — somatostatin analogues, targeted drugs, chemotherapy, and Lu-177 DOTATATE. This plain-language guide explains how each option works, what the trial evidence shows, and which questions to ask before you decide.
What Are the Real-World Side Effects of Lu-177 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer — and How Do Doctors Manage Them?
Lu-177 PSMA therapy is generally well-tolerated, but it does cause side effects that patients and caregivers need to understand. Learn what the clinical evidence says about dry mouth, fatigue, blood count changes, and how medical teams manage each one.
My Bone Metastases Are Causing Severe Pain — Can Lu-177 PSMA Therapy Help, and What Does the Evidence Say About Pain Relief?
Bone pain from prostate cancer metastases can be relentless. Here is what the clinical trial evidence — including the landmark VISION and PSMAfore studies — actually shows about whether Lu-177 PSMA therapy may help reduce that pain and protect quality of life.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.